Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECLIPSE trial of atogepant for acute migraine treatment
jRCT2051240004Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in migraine comparing Atogepant double-blind arm with Placebo double-blind arm (2 arms). Primary endpoint: Percentage of participants achieving pain freedom at 2 hours after the double-blind dose for the first attack. Started Apr 2024; status: recruiting.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on jRCT2051240004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240004.